Old Web
English
Sign In
Acemap
>
Paper
>
Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study
Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study
2019
Youn H. Kim
Martine Bagot
Pier Luigi Zinzani
Madeleine Duvic
Stephen Morris
Ellen Kim
Amy Musiek
Pablo L. Ortiz-Romero
Craig A. Elmets
Herbert Eradat
Nina Magnolo
Julia Scarisbrick
Stéphane Dalle
David C. Fisher
Michi M. Shinohara
Brian Poligone
Barbara Pro
Pietro Quaglino
Nishitha Reddy
Brigitte Dreno
Larisa J. Geskin
Ahmad Halwani
Amit Khot
Marie Beylot-Barry
Neil J. Korman
Frederick Lansigan
Steven M. Horwitz
Zanetta S. Lamar
Alison J. Moskowitz
Jillian Wells
Oleg E. Akilov
Dolores Caballero
Richard A Cowan
Reinhard Dummer
Mary Jo Lechowicz
Francine M. Foss
Lars Iversen
Tomomitsu Miyagaki
Ryan A. Wilcox
Pierluigi Porcu
Maarten H. Vermeer
Sunil Abhyankar
Yukihiko Kato
Theresa R. Pacheco
Shigetoshi Sano
Basem M. William
Timothy S. Fenske
Noriko Fukuhara
Koji Habe
Toshihisa Hamada
Eiji Kiyohara
Bryone J. Kuss
Adam Lerner
Lawrence A. Mark
Javier Munoz
Hiroyuki Okamoto
Christiane Querfeld
Jiro Uehara
Hisashi Uhara
Kentaro Yonekura
Auris Huen
Kensei Tobinai
Yoshiki Tokura
Erin Boh
Jan P. Nicolay
Hidefumi Wada
Mollie Leoni
Takahiro Ito
Fiona Herr
Lubomir Sokol
Keywords:
Immunology
Medicine
Mycosis fungoides
Mogamulizumab
Dermatology
Aspartate Aminotransferases
physical health
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI
[]